Key Takeaways
- Tara Schwetz, deputy director at NIH, has been placed on administrative leave amid leadership changes.
- Her departure follows significant exits in NIH’s senior leadership and other federal health agencies.
- Schwetz played a key role in establishing ARPA-H, increasing its funding significantly since 2022.
NIH Leadership Changes Create Uncertainty
Tara Schwetz, Ph.D., the deputy director for program coordination, planning, and strategic initiatives at the National Institutes of Health (NIH), is reportedly on administrative leave as of 5 p.m. today. This news coincides with the Senate confirming Dr. Jayanta Bhattacharya, President Donald Trump’s appointee, to lead the NIH. Schwetz’s departure is notable, as she is the latest high-profile official to leave the agency, marking a shift in leadership within the NIH during Trump’s second term.
Since the beginning of the administration, the NIH has seen significant turnover in its senior leadership. In February, two other prominent officials departed: Michael Lauer, M.D., the deputy director for extramural research, and Larry Tabak, Ph.D., the principal deputy director, both leaving amidst substantial layoffs affecting federal health agencies.
This trend extends beyond the NIH. Other important departures from government health organizations in 2023 include Dr. Renee Wegrzyn, Director of the Advanced Research Projects Agency for Health (ARPA-H), and various key leaders from the FDA, including Patrizia Cavazzoni, M.D., and Celia Witten, M.D., Ph.D. These exits contribute to growing concerns about stability within federal health organizations as they navigate ongoing challenges in public health.
Tara Schwetz was appointed to her role in 2023 and is widely recognized for her efforts in establishing ARPA-H in 2022. This innovative funding agency, initiated with strong support from former President Joe Biden, began with a budget of $1 billion, which has since expanded to $2.5 billion as of May 2023. Under her leadership, ARPA-H aimed to foster connections between the public and private sectors to expedite biomedical research processes.
As of now, there has been no official comment from the Department of Health and Human Services (HHS) regarding Schwetz’s leave, leaving many questions unanswered about the direction of NIH and federal health agencies moving forward. The continued reshuffling of leadership is likely to have implications for health research prior to the looming challenges these organizations face in supporting public health initiatives effectively.
The content above is a summary. For more details, see the source article.